Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
FLAURIX, NEW ANTI FLU SHOT

Fluarix, anti-flu shot by Glaxo approved

Fluarix is currently distributed in 79 countries, will be available exclusively in prefilled Tip-Lok syringes. 

 

BY OUR PHARMA CORRESPONDENT

2 September, 2005: In a major step toward increasing flu vaccine supply in the United States, the U.S. Food and Drug Administration has approved GlaxoSmithKline’s influenza vaccine, Fluarix for distribution in time for the 2005/2006 influenza season. 

Fluarix, indicated for adults 18 and older against influenza disease, is currently distributed in 79 countries, will be available exclusively in prefilled Tip-Lok syringes. 

The FDA reviewed safety and immunogenicity data from a phase III clinical trial which studied Fluarix in approximately 1,000 adults in the United States aged 18 to 64. This randomized, double-blind, placebo-controlled study showed Fluarix to be safe and immunogenic. 
Many respiratory diseases occur every winter, but influenza is one of the most severe. The illness is easily passed from one person to another through the air by tiny droplets released when an infected individual coughs or sneezes. Most people recover fully within a week or two, but the risk of complications is elevated in very young, very old and chronically ill persons. 

Although epidemics of flu happen in most years, the beginning, severity and length of the epidemic can vary widely from year to year. Before a season begins, it is not possible to accurately predict the features of any season. While October or November is the best time to get vaccinated, getting influenza vaccine in December, or even later, can be beneficial in most years. Flu season can begin as early as October and last as late as May. People who should receive the influenza vaccine include the very young, people 50 years of age or older, the chronically ill, women who will be pregnant during influenza season and all healthcare workers. 

In addition to the public health threat influenza poses, the disease has economic repercussions. An average of approximately 226,000 influenza-related excess hospitalizations occurred per year in the United States between 1979 and 2001. Influenza epidemics can have a significant impact on theU.S.economy, as influenza infection results in an average of 2.8 lost workdays per episode, or $398 in lost wages for the average worker. Recent estimates put the cost of influenza epidemics to the economy at $71 —$167 billion per year. 

A GSK release alerted that Fluarix should not be administered to anyone with known systemic hypersensitivity reactions to eggs, egg products, egg or chicken proteins, or any component of Fluarix, or to anyone who has had a life-threatening reaction to previous administration of any influenza vaccine. The most common adverse event in a clinical trial was pain at the injection site. Less common adverse events were muscle aches, fatigue, and headache. Most adverse events in clinical trials were mild and self-limiting.
Shipments that would begin going out immediately for its Fluarix vaccine and that it would be priced in line with other shots currently marketed in the United States, a GSK spokesperson said in the release.

Federal health officials want to prevent a recurrence of the 2004-5 season when the expected supply of 100 million shots was cut almost in half after British health regulators closed Chiron's plant. 

Lawmakers held hearings earlier this year to call for a steady supply of vaccine against the flu, which is estimated to kill 36,000 Americans and hospitalize 200,000 annually.
Sanofi-Aventis, the biggest supplier to the United States, delivered about 58 million of the 61 million doses that were available in the 2004-5 season. Sanofi and Glaxo have both begun increasing production in plants in the United States and Europe.

Glaxo plans to double its annual flu shot production to 80 million shots by 2008. Sanofi is doubling an American plant's annual capacity to 100 million shots for the 2009 season, and may raise production capacity at a French plant.

The ID Biomedical Corporation, which makes flu shots for Canada, said in July that the F.D.A. granted the company an accelerated approval process for its Fluviral shot. The company expects to make as many as 25 million doses for the United States next year and as many as 40 million in 2007

BY OUR PHARMA CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

Diseases - Alzheimer's, Parkisonson's and Obesity

Contraception and Abortion News

LATEST UPDATES

Anti fungal terbinafine launched in Europe: Actavis

HIV entry blocking drug data encouraging: Progenics

Allegra generic to be launched in US

Long-acting pain drug data positive: Pain Therapeutics

New kidney cancer drug seeks EU nod

Inhaled insulin may get US FDA clearance

A vaccine against fungus is on way

Enzyme stops progression of HIV in survivors, confirms study

Aclasta found faster-acting in Paget's disease treatment

Beta blocker can start therapy in heart failure: Merck

Halobetasol generic launched in US

Anemia drug darbepoetin's late-stage studies begin: Amgen

Cholesterol generic gets marketing nod in US: Par

Aricept for severe Alzheimer’s disease too: Eisai

Bone regeneration trials begin in US:Mesoblast

New dye to detect early Alzheimer's

Breast forming gene discovered

Thyroid drug to be supplied by IVAX in US

Rituxan, cancer drug can treat rheumatoid arthritis

Yasminelle, low-dose oral contraceptive approved in the Netherlands

Fluarix, anti-flu shot by Glaxo approved

Increlex, drug to treat `abnormally short’ kids approved in US

Anti-HIV drugs prices cut: Gilead

US FDA approves Takeda’s drug combo for type 2 diabetes

Novartis’ drug for breast cancer recurrence to be given priority review in US

US puts off decision on contraceptive pill again

Shire’s ADHD drug Adderall back on list in Canada

WHO calls for emergency action to halt TB in Africa

Some of the Vioxx suits may be settled: Merck

Nasdaq delists Able on bankruptcy filing

Hospira ships ceftriaxone generics to US

Renovis stops sciatica drug studies

Merck sets up generic arm Genpharm in US

Morning after pills still not within easy reach in US

New cancer combo therapy results positive:OXiGENE

Aceon approved for heart disease treatment in US

Cell Therapeutics to seek approval for lung cancer therapy in US and Europe

Anti-depressant Seroxat defended by GSK against new findings

Vioxx verdict: Merck’s defeat to trigger thousands of lawsuits from US, UK

Aspirin stops colon cancer, but may trigger bleeding

New blood test method approved in US

Skin disease drug turns into anti-tumor therapy for cancer

Step-by-Step instructions for dealing with Asthma Attacks

Potential Alzheimer's Disease drugs under investigation

New Molecule may help obese lose weight

Paxil (Paroxetine) may heighten suicide risks, finds study

"Breast cancer chances higher due to fried chips"

Safety alert on Gambro Dasco’s Prisma renal system

Merck responsible for Vioxx death: Jury

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us